Last reviewed · How we verify
CAR.B7-H3T cells infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CAR.B7-H3T cells infusion (CAR.B7-H3T cells infusion) — UNC Lineberger Comprehensive Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CAR.B7-H3T cells infusion TARGET | CAR.B7-H3T cells infusion | UNC Lineberger Comprehensive Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CAR.B7-H3T cells infusion CI watch — RSS
- CAR.B7-H3T cells infusion CI watch — Atom
- CAR.B7-H3T cells infusion CI watch — JSON
- CAR.B7-H3T cells infusion alone — RSS
Cite this brief
Drug Landscape (2026). CAR.B7-H3T cells infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/car-b7-h3t-cells-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab